Year: 2016
Language: Arabic
This resource is also available in: الإنجليزية الفرنسية الروسية الأسبانية الصينية المبسطة
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
Listen to this 2-hour webinar presented on April 22, 2021 to learn about global topics related to bleeding disorders. The
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking,
Also Available In: Japanese A national tender system is a cost-effective system for the purchase of products or services, such
Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic
Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.
